Analyst firms · Jefferies · RLAY
Jefferies RLAY price target and rating history
Relay Therapeutics Inc. (RLAY) · Health Care
Jefferies rates Relay Therapeutics Inc. (RLAY) Buy with a $16 price target, as of its latest action on Sep 10, 2024. It has published 3 rating actions on RLAY since June 2022, including 2 upgrades and 0 downgrades. Across 3 firms with a RLAY price target in the last 12 months, the median target is $14.
- Current rating
- Buy
- Price target
- $16
- Median target, all firms
- $14
- Actions on RLAY
- 3
Jefferies price target on RLAY
Every Jefferies rating on RLAY
- Sep 10, 2024
- Apr 20, 2023
- Jun 6, 2022
How other firms rate RLAY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Buy | $29 | Jul 16, 2026 |
| Oppenheimer | Outperform | $14 | Jan 26, 2026 |
| Wells Fargo | Overweight | $13 | Dec 12, 2025 |
Questions about Jefferies and RLAY
- What is Jefferies's price target for RLAY?
- Jefferies's latest stated price target for Relay Therapeutics Inc. (RLAY) is $16, from its action on Sep 10, 2024.
- What is Jefferies's rating on RLAY?
- Jefferies rates RLAY Buy, a bullish rating, as of Sep 10, 2024.
- When did Jefferies last change its view on RLAY?
- On Sep 10, 2024, Jefferies upgrades to Buy from Hold, price target $10.60 to $16.
- How does Jefferies's RLAY target compare with other analysts?
- Across 3 firms with a RLAY price target in the last 12 months, the median target is $14.
More RLAY rating histories
All Jefferies ratingsRLAY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.